[
  {
    "ts": null,
    "headline": "Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax",
    "summary": "Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The update follows a media report on Friday that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine Adverse Event Reporting System. The data from an ongoing Phase 4 trial evaluating the safety, tole",
    "url": "https://finnhub.io/api/news?id=08d9fb14e8acaafb6ea0e7d9755101b3952918233b3bb76c54fa8aa4a2eca909",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758144664,
      "headline": "Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax",
      "id": 136797685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The update follows a media report on Friday that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine Adverse Event Reporting System. The data from an ongoing Phase 4 trial evaluating the safety, tole",
      "url": "https://finnhub.io/api/news?id=08d9fb14e8acaafb6ea0e7d9755101b3952918233b3bb76c54fa8aa4a2eca909"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response",
    "summary": "Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.",
    "url": "https://finnhub.io/api/news?id=4e8cda0cb7b88c74d1caf45046acd4fed2d44f4bfb67ad1bd11b03f4caed8373",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758121440,
      "headline": "MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response",
      "id": 136789966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.",
      "url": "https://finnhub.io/api/news?id=4e8cda0cb7b88c74d1caf45046acd4fed2d44f4bfb67ad1bd11b03f4caed8373"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Plunges Around 24% in Six Months: How to Play the Stock",
    "summary": "Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.",
    "url": "https://finnhub.io/api/news?id=99ba2f51880573d5173b9a96f1a667abe614fcf001016d583fd9e4fbced86415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119280,
      "headline": "Vertex Plunges Around 24% in Six Months: How to Play the Stock",
      "id": 136789349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.",
      "url": "https://finnhub.io/api/news?id=99ba2f51880573d5173b9a96f1a667abe614fcf001016d583fd9e4fbced86415"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD",
    "summary": "Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”",
    "url": "https://finnhub.io/api/news?id=3573f7245ce873d1d8b103fba1481936dfe22f8834a5dde4155c7cd274ead975",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758111840,
      "headline": "Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD",
      "id": 136789896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”",
      "url": "https://finnhub.io/api/news?id=3573f7245ce873d1d8b103fba1481936dfe22f8834a5dde4155c7cd274ead975"
    }
  }
]